The NFL and NFL Players Association are jointly reviewing how the Philadelphia Eagles handled Jalen Hurts’ blood-clot diagnosis. The review is underway, but the league and union have not announced findings or conclusions.
Hurts was placed on injured reserve and is expected to miss the rest of the 2026 season after medical testing identified deep vein thrombosis and bilateral pulmonary emboli. The league and players’ union confirmed their joint review on October 25 after the NFLPA called for an investigation. The immediate priority remains Hurts’ health and recovery; the review will examine the process and medical timeline.
What has been confirmed so far?
The NFL and NFLPA said they are working together to review the handling of the diagnosis after the players’ union requested an investigation. NFL Commissioner Roger Goodell said on October 21 that the league welcomed the review and that the league’s chief medical officer had examined the steps taken. Those public statements describe the parties’ positions; they are not the same as a final independent finding.
The Eagles have said Hurts’ medical issue followed an injury to his calf area during an October 4 game against the Los Angeles Rams. Hurts reported the injury to team medical staff after practice on October 8. After further evaluation, he travelled to London for the game against Jacksonville and was initially diagnosed by specialists there with a left calf superficial vein thrombosis. He played on October 11, before subsequent testing identified deep vein thrombosis and blood clots in both lungs.
The review is ongoing. Publicly available information does not establish a final conclusion about whether the club or its medical staff breached a protocol.
Timeline: the key dates
| Date | Publicly reported development |
|---|---|
| Oct 4 | Hurts is reported to have taken a cleat to the calf area during a game against the Rams. |
| Oct 8 | Hurts informed the Eagles’ medical staff of the injury after practice. |
| Oct 9 | Hurts returned to practice before the team travelled to London. |
| Oct 11 | Hurts played against Jacksonville after an initial diagnosis in London. |
| Oct 21 | Goodell publicly said the league welcomed an investigation into the handling of the case. |
| Oct 25 | The NFL and NFLPA confirmed they were working together to review the timeline and process. |
Why the diagnosis matters
Deep vein thrombosis refers to a blood clot in a deep vein, while a pulmonary embolism occurs when a clot blocks a blood vessel in the lungs. These are serious medical conditions. The Eagles and Hurts’ representatives have said the quarterback will not take part in football activities while he is on blood thinners, and he is expected to miss the remainder of the season.
This article is not medical advice. The relevant questions for the league review concern the reported timeline, assessments and protocols—not speculation about a player’s private medical details beyond what has been publicly confirmed.
What remains unresolved?
- The review’s scope and timetable: The public announcement did not set a date for findings.
- Protocol assessment: The review may establish which procedures were followed; no final result has been announced publicly.
- Responsibility: It would be premature to declare fault before the process is completed.
- Recovery: Hurts’ treatment and return-to-play decisions are medical matters, and no timetable should be assumed.
What this means for Philadelphia
Hurts’ absence changes the Eagles’ season on the field, but the immediate priority is his recovery. The football implications—quarterback depth, play-calling, leadership and the team’s playoff position—will develop week by week. The medical review is a separate process, and the two should not be conflated.
Sportimatic takeaway
The most responsible reading is to separate the confirmed medical timeline from the unresolved review. The league and union have acknowledged the issue and are examining the handling of the case. Until findings are published, claims about violations or individual fault remain unproven.
Sources and further reading
Updated October 29, 2026. This report reflects publicly available statements; no final findings of the review have been announced.




